Beta3 Agonist Treatment in Chronic Pulmonary Hypertension Secondary to Heart Failure

NCT02775539 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

80

Enrollment

OTHER

Sponsor class

Conditions

Pulmonary Hypertension
Mirabegron
Heart Failure
Pulmonary Vascular Resistance Abnormality

Interventions

DRUG: Mirabegron
DRUG: Placebo

Sponsor

Fundación Centro Nacional de Investigaciones Cardiovasculares Carlos III

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]